HS-10502 / Jiangsu Hansoh Pharma - LARVOL DELTA

HS-10502 Combination Treatment in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=157 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Gastric Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

HS-10502 Combination Treatment in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=154 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Breast Cancer • Gastric Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

Hansoh Pharmaceuticals' three new Category 1 cancer drugs approved for clinical trials! PARP1 inhibitor and ADC combination therapy [Google translation] (Sina Corp) - "On August 23, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that three of Hansoh Pharmaceutical's Category 1 cancer drugs under development were approved for clinical trials. They are: (i) HS-10502 tablets, combined with enzalutamide or abiraterone acetate tablets (II), or apatinib or albumin-paclitaxel or docetaxel or irinotecan liposome or HS-20093 or HS-20089 or HS-20089 + bevacizumab for the treatment of patients with advanced solid tumors; (ii) HS-20089 for injection , combined with HS-10502 tablets, is intended for the treatment of patients with advanced solid tumors; (iii) HS-20093 for injection , combined with HS-10502 tablets, is intended for the treatment of patients with advanced solid tumors."

New trial • Solid Tumor

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=318 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • HRD • MUC16

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=318 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Solid Tumor • HRD • MUC16